- Home
- DTIL vs RANI Comparison
DTIL vs RANI Comparison
Compare DTIL & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- RANI
- Stock Information
- Founded
- DTIL 2006
- RANI 2012
- Country
- DTIL United States
- RANI United States
- Employees
- DTIL N/A
- RANI N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- DTIL Health Care
- RANI Health Care
- Exchange
- DTIL Nasdaq
- RANI Nasdaq
- Market Cap
- DTIL 44.1M
- RANI 41.6M
- IPO Year
- DTIL 2019
- RANI 2021
- Fundamental
- Price
- DTIL $4.96
- RANI $1.31
- Analyst Decision
- DTIL Strong Buy
- RANI Strong Buy
- Analyst Count
- DTIL 3
- RANI 5
- Target Price
- DTIL $37.67
- RANI $11.80
- AVG Volume (30 Days)
- DTIL 1.3M
- RANI 420.9K
- Earning Date
- DTIL 11-04-2024
- RANI 11-14-2024
- Dividend Yield
- DTIL N/A
- RANI N/A
- EPS Growth
- DTIL N/A
- RANI N/A
- EPS
- DTIL 1.45
- RANI N/A
- Revenue
- DTIL $75,096,000.00
- RANI N/A
- Revenue This Year
- DTIL $52.95
- RANI N/A
- Revenue Next Year
- DTIL N/A
- RANI N/A
- P/E Ratio
- DTIL $2.57
- RANI N/A
- Revenue Growth
- DTIL 43.62
- RANI N/A
- 52 Week Low
- DTIL $3.61
- RANI $1.24
- 52 Week High
- DTIL $19.43
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- DTIL 46.54
- RANI 35.89
- Support Level
- DTIL $5.10
- RANI $1.24
- Resistance Level
- DTIL $7.44
- RANI $1.61
- Average True Range (ATR)
- DTIL 0.66
- RANI 0.11
- MACD
- DTIL 0.14
- RANI 0.02
- Stochastic Oscillator
- DTIL 35.25
- RANI 18.92
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.